LENSAR, Inc. develops and markets robotic laser systems for cataract treatment and astigmatism management. The company’s product portfolio includes the ALLY Robotic Cataract Laser System, the LENSAR Laser System with Streamline IV and IntelliAxis, related software, and associated consumable components.
Recurring company updates focus on ALLY system placements, installed-base activity, procedure volume, and recurring revenue from procedure, lease, and service sources. LENSAR news also includes quarterly and annual results, medical-device regulatory disclosures, material agreements, capital-structure matters, and governance actions such as equity inducement awards.
LENSAR (LNSR) reported third-quarter 2026 revenue of $14.1 million, down 1% year over year as lower system sales offset recurring growth. Recurring revenue rose 17% to $12.6 million, representing 89% of revenue versus 75% a year earlier. Procedure volume increased 12% to 52,545. The net loss widened to $4.723 million, or $0.38 per share, from $3.713 million, or $0.31 per share. Adjusted EBITDA, a non-GAAP earnings measure, improved to $1.669 million from negative $298,000.
LENSAR placed 10 ALLY systems, bringing its ALLY installed base to 225, up 22% year over year; its total laser installed base reached 450. Another 12 ALLY systems awaited installation at September 30. Cash, cash equivalents and investments totaled $12.6 million, versus $18.0 million at December 31, 2025. Nine-month revenue rose to $44.054 million from $42.410 million, while net income reached $35.144 million versus a $32.822 million loss.
LENSAR (Nasdaq: LNSR) will release its third-quarter 2026 financial results before market open on Tuesday, November 10, 2026. Management will host a conference call and webcast at 8:30 am ET that day to discuss the results and recent operational highlights. An archived version will be available on the company’s website after the live webcast.
LENSAR (Nasdaq: LNSR) reported second quarter 2026 revenue of $16.5 million, up 18% year over year, with recurring revenue of $13.7 million, up 20% and representing 83% of total revenue. Procedure revenue rose 23% to $10.2 million on procedure volume of 58,682, up 13% versus Q2 2025.
The total laser installed base reached 445 systems, including 215 ALLY Robotic Cataract Laser Systems, a 30% increase year over year, driven by 10 ALLY placements in Q2 and a backlog of 13 systems. LENSAR delivered net income of $3.5 million versus a $1.8 million loss and Adjusted EBITDA of $3.6 million versus a $0.3 million loss. Cash, cash equivalents and investments were $13.6 million as of June 30, 2026, compared with $18.0 million at December 31, 2025.
LENSAR (Nasdaq: LNSR) will release its second quarter 2026 financial results before the market opens on Thursday, August 13, 2026. Management will hold a conference call and webcast at 8:30 a.m. ET the same day to discuss results, recent developments, and strategic initiatives.
LENSAR (Nasdaq: LNSR) reported Q1 2026 results: total revenue $13.4M, recurring revenue $12.6M (≈94% of total), and net income of $36.3M or $1.56 basic per share. The company placed 7 ALLY systems in Q1, bringing the ALLY installed base to ~205 and total laser base to ~440 systems.
SG&A and operating expenses fell sharply year-over-year, driven by reversal of acquisition-related costs after a terminated merger; cash and investments were $13.5M as of March 31, 2026.
LENSAR (Nasdaq: LNSR) will report first quarter 2026 financial results before market open on Friday, May 8, 2026. Management will host a conference call and webcast at 8:30 am ET the same day to discuss results, corporate and operational highlights, and strategic initiatives.
Registration is required for telephone participation and the live webcast is available under Events & Presentations on the company investor relations website. A replay will be available through May 15, 2026.
LENSAR (Nasdaq: LNSR) reported fourth-quarter and full-year 2025 results, highlighting recurring revenue of $46.3 million for the year, a 15% increase versus 2024, and recurring revenue representing 79% of total revenue for both Q4 and FY2025. ALLY installed base reached approximately 200 systems (a 48% increase year-over-year) with a backlog of 13 systems and total combined installed base of ~435 systems, up 13% year-over-year.
Worldwide procedure volume rose ~22% in 2025. Q4 total revenue was $16.0 million; net loss was $1.5 million for Q4 2025. Cash and investments totaled $18.0 million at year-end. The company and Alcon executed a termination agreement under which LENSAR will retain a $10.0 million merger deposit.
Alcon (SIX/NYSE: ALC) and LENSAR (NASDAQ: LNSR) agreed to terminate their previously announced merger. The companies said the nearly one-year regulatory review and the FTC's opposition made the transaction unattractive to pursue.
Alcon cited delay and associated costs and reaffirmed its commitment to advancing cataract surgery technologies.
LENSAR (Nasdaq: LNSR) announced termination of its merger agreement with Alcon Research, LLC, after the Federal Trade Commission indicated it intends to seek to enjoin the acquisition. The companies mutually agreed to end the deal because required U.S. regulatory approvals were unlikely by the April 23, 2026 outside date (or extended July 23, 2026).
The company will retain the $10.0 million deposit from the merger agreement and plans to report fourth quarter and full-year 2025 results and a strategic update on March 31, 2026, including a conference call at 8:30 a.m. ET.
LENSAR (Nasdaq: LNSR) provided an update on its pending acquisition by Alcon. The companies remain engaged with the U.S. Federal Trade Commission after receiving a Second Request for additional information and documentary material.
In light of the ongoing review, LENSAR currently expects the transaction to close in the first half of 2026, subject to satisfaction of closing conditions including FTC regulatory approval.